Cipla Targets Global Respiratory Biosimilars With Kemwell JV
Indian Firm Will Bring Its ‘Respiratory Prowess’ To Planned Venture
Cipla is to establish a new company with CDMO Kemwell Biopharma to develop and launch biosimilars for the global market, especially in the respiratory space, where Cipla has built a considerable presence for inhalation products.
You may also be interested in...
Cipla: $500m North American Sales Boost Possible In Five Years
Cipla’s recent US approval with a partner for its 505(b)(2) hybrid lanreotide injection product signaled the firm’s intentions to broaden in the peptides and injectables space, as it looks to add hundreds of millions to its revenue base by Cipla’s 2027 financial year.
Deal Watch: Lilly Teams Up With Lycia In Protein Degradation
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
Cipla Resets Biosimilars Interest, Readies Respiratory-Focused JV
Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.